Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?
Yıl: 2022 Cilt: 54 Sayı: 1 Sayfa Aralığı: 50 - 53 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2022.21292 İndeks Tarihi: 24-06-2022
Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?
Öz: Objective: Cognitive developmental delay is a picture of the group of early-onset chronic diseases that affect
1.5-10% of children. Autism spectrum disorders are neurodevelopmental diseases with a genetic basis and
abnormal brain development, characterized by disorders in areas that make up interpersonal relationships,
such as communication, social cognition, and processing of emotional signals. Immune system dysfunction is
thought to play a role in the pathogenesis of some neurological disorders, including autism. Progranulin is
thought to be a regulator of the innate immune response. The purpose of this study was to look at plasma
levels of progranulin, an anti-inflammatory neurotrophic factor, in children with autism spectrum disorder
and cognitive developmental delay.
Materials and Methods: The study was conducted on 52 children who were patients and 35 healthy children. Of the 52 children of the patient group, 32 were diagnosed with CDD and 20 were diagnosed with
cognitive developmental delay–autism spectrum disorder. Serum progranulin concentrations were measured
using a human-specific sandwich enzyme-linked immunosorbent assay.
Results: Serum progranulin concentration was statistically lower in the patient group (110.746 ± 26.04) than
in the healthy control group (137.346 ± 30.02). There was a statistically significant difference between the
groups in levels of serum progranulin (P=.000). Receiver operating characteristic analysis was performed
to evaluate the potential of progranulin as a biomarker to distinguish patients with cognitive developmental delay–autism spectrum disorder from healthy children. It detected a moderate area under the curve
(0.743 ± 0.06) value and a more significant P value for progranulin (P=.000).
Conclusion: Progranulin deficiency in patients with autism spectrum disorder–cognitive developmental
delay may result in decreased neurotrophic support for many years, with cumulative damage associated
with unregulated inflammation that may play a role in autism spectrum disorder–cognitive developmental
delay. We believe that low progranulin levels could be a biomarker for autism spectrum disorder–cognitive
developmental delay.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Rydz D, Shevell MI, Majnemer A, Oskoui M. Developmental screening. J Child Neurol. 2005;20(1):4-21. [CrossRef]
- 2. Özbaran B, KÖSe SG, Erermiş S. Yaygın gelişimsel bozukluklarda sosyal biliş. Klin Psikofarmakol Bul. 2009;19(3):322-331.
- 3. Cohly HHP, Panja A. Immunological findings in autism. Int Rev Neurobiol. 2005;71:317-341. [CrossRef]
- 4. Al-ayadhi LY, Mostafa GA. Increased serum osteopontin levels in autistic children: relation to the disease severity. Brain Behav Immun. 2011;25(7):1393-1398. [CrossRef]
- 5. Mostafa GA, El-Sayed ZA, El-Aziz MM, ElSayed MF. Serum anti-myelin—associated glycoprotein antibodies in Egyptian autistic children. J Child Neurol. 2008;23(12):1413-1418. [CrossRef]
- 6. Mostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM. Oxidative stress in Egyptian children with autism: relation to autoimmunity. J Neuroimmunol. 2010;219(1-2):114-118. [CrossRef]
- 7. Toh H, Cao M, Daniels E, Bateman A. Expression of the growth factor progranulin in endothelial cells influences growth and development of blood vessels: a novel mouse model. PLoS ONE. 2013;8(5):e64989. [CrossRef]
- 8. Jacova C, Hsiung GY, Tawankanjanachot I, et al. Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology. 2013;81(15):1322-1331. [CrossRef]
- 9. Lan J, Hu Y, Wang X, et al. Abnormal spatiotemporal expression pattern of progranulin and neurodevelopment impairment in VPA-induced ASD rat model. Neuropharmacology. 2021;196:108689. [CrossRef]
- 10. Kessenbrock K, Fröhlich L, Sixt M, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest. 2008;118(7):2438-2447. [CrossRef]
- 11. Nothan C. Neutrophils and immunity: challenges and port unities. Nat Rev Immunol. 2006;6(6):173.
- 12. Jian J, Konopka J, Liu C. Insights into the role of progranulin in immunity, infection, and inflammation. J Leukoc Biol. 2013;93(2):199-208. [CrossRef]
- 13. Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell. 2002;111(6):867-878. [CrossRef]
- 14. Courchesne E, Mouton PR, Calhoun ME, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA. 2011;306(18):2001- 2010. [CrossRef]
- 15. Fu Z, Tu Y, Di X, et al. Transient increased thalamic-sensory connectivity and decreased whole-brain dynamism in autism. NeuroImage. 2019;190:191-204. [CrossRef]
- 16. Li L, Huang L, Vergis AL, et al. IL-17 produced by neutrophils regulates IFN-γ–mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010;120(1):331-342. [CrossRef]
- 17. Progranulin (PGRN). Sci-Bus Exch. 2008;1(12):289. [CrossRef]
- 18. Wang XM, Zeng P, Fang YY, Zhang T, Tian Q. Progranulin in neurodegenerative dementia. J Neurochem. 2021;158(2):119-137. [CrossRef]
- 19. Arrant AE, Onyilo VC, Unger DE, Roberson ED. Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis. J Neurosci. 2018;38(9):2341- 2358. [CrossRef]
- 20. Bartoletti-Stella A, De Pasqua S, Baiardi S, et al. Characterization of novel progranulin gene variants in Italian patients with neurodegenerative diseases. Neurobiol Aging. 2021;97:145.e7-145. e15. [CrossRef]
- 21. Van Damme P, Van Hoecke A, Lambrechts D, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol. 2008;181(1):37-41. [CrossRef]
- 22. Daniel R, Daniels E, He Z, Bateman A. Progranulin (acrogranin/PC cell derived growth factor/ granulin epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development. Dev Dyn. 2003;227(4):593-599. [CrossRef]
- 23. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916-919. [CrossRef]
- 24. Ahmed Z, Mackenzie IRA, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation. 2007;4(1):7. [CrossRef]
- 25. Yin FF, Banerjee R, Thomas B, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207(1):117-128. [CrossRef]
- 26. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry. 2005;17(6):485-495. [CrossRef]
- 27. Toh H, Chitramuthu BP, Bennett HPJ, Bateman A. Structure, function, and mechanism of progranulin; the brain and beyond. J Mol Neurosci. 2011;45(3):538-548. [CrossRef]
- 28. Cui Y, Hettinghouse A, Liu CJ. Progranulin: a conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases. Cytokine Growth Factor Rev. 2019;45:53-64. [CrossRef]
- 29. Elia LP, Reisine T, Alijagic A, Finkbeiner S. Approaches to develop therapeutics to treat frontotemporal dementia. Neuropharmacology. 2020;166:107948. [CrossRef]
- 30. Malik BR, Maddison DC, Smith GA, Peters OM. Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Mol Brain. 2019;12(1):100. [CrossRef]
APA | OZGERIS F, KURT N, Ucuz İ, YILMAZ K, KELEŞ M, Cayir A, Dursun O (2022). Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. , 50 - 53. 10.5152/eurasianjmed.2022.21292 |
Chicago | OZGERIS FATMA BETÜL,KURT Nezahat,Ucuz İlknur,YILMAZ Kübra KOÇAK,KELEŞ Mevlüt Sait,Cayir Atilla,Dursun Onur Burak Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. (2022): 50 - 53. 10.5152/eurasianjmed.2022.21292 |
MLA | OZGERIS FATMA BETÜL,KURT Nezahat,Ucuz İlknur,YILMAZ Kübra KOÇAK,KELEŞ Mevlüt Sait,Cayir Atilla,Dursun Onur Burak Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. , 2022, ss.50 - 53. 10.5152/eurasianjmed.2022.21292 |
AMA | OZGERIS F,KURT N,Ucuz İ,YILMAZ K,KELEŞ M,Cayir A,Dursun O Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. . 2022; 50 - 53. 10.5152/eurasianjmed.2022.21292 |
Vancouver | OZGERIS F,KURT N,Ucuz İ,YILMAZ K,KELEŞ M,Cayir A,Dursun O Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. . 2022; 50 - 53. 10.5152/eurasianjmed.2022.21292 |
IEEE | OZGERIS F,KURT N,Ucuz İ,YILMAZ K,KELEŞ M,Cayir A,Dursun O "Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?." , ss.50 - 53, 2022. 10.5152/eurasianjmed.2022.21292 |
ISNAD | OZGERIS, FATMA BETÜL vd. "Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?". (2022), 50-53. https://doi.org/10.5152/eurasianjmed.2022.21292 |
APA | OZGERIS F, KURT N, Ucuz İ, YILMAZ K, KELEŞ M, Cayir A, Dursun O (2022). Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. Eurasian Journal of Medicine, 54(1), 50 - 53. 10.5152/eurasianjmed.2022.21292 |
Chicago | OZGERIS FATMA BETÜL,KURT Nezahat,Ucuz İlknur,YILMAZ Kübra KOÇAK,KELEŞ Mevlüt Sait,Cayir Atilla,Dursun Onur Burak Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. Eurasian Journal of Medicine 54, no.1 (2022): 50 - 53. 10.5152/eurasianjmed.2022.21292 |
MLA | OZGERIS FATMA BETÜL,KURT Nezahat,Ucuz İlknur,YILMAZ Kübra KOÇAK,KELEŞ Mevlüt Sait,Cayir Atilla,Dursun Onur Burak Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. Eurasian Journal of Medicine, vol.54, no.1, 2022, ss.50 - 53. 10.5152/eurasianjmed.2022.21292 |
AMA | OZGERIS F,KURT N,Ucuz İ,YILMAZ K,KELEŞ M,Cayir A,Dursun O Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. Eurasian Journal of Medicine. 2022; 54(1): 50 - 53. 10.5152/eurasianjmed.2022.21292 |
Vancouver | OZGERIS F,KURT N,Ucuz İ,YILMAZ K,KELEŞ M,Cayir A,Dursun O Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?. Eurasian Journal of Medicine. 2022; 54(1): 50 - 53. 10.5152/eurasianjmed.2022.21292 |
IEEE | OZGERIS F,KURT N,Ucuz İ,YILMAZ K,KELEŞ M,Cayir A,Dursun O "Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?." Eurasian Journal of Medicine, 54, ss.50 - 53, 2022. 10.5152/eurasianjmed.2022.21292 |
ISNAD | OZGERIS, FATMA BETÜL vd. "Is Serum Progranulin Level a Biomarker in Autism and Cognitive Development Disorders?". Eurasian Journal of Medicine 54/1 (2022), 50-53. https://doi.org/10.5152/eurasianjmed.2022.21292 |